Amyloid-like RIP1/RIP3 RHIM Fragments' Characterization and Application as a Drug Depot

Area of Science:

• Biochemistry and Molecular Biology
• Biomaterials Science
• Cellular Biology

Background:

• Protein aggregation, including amyloid aggregates, is crucial in both disease and normal cellular functions like necroptosis via Receptor-interacting protein kinases 1 and 3 (RIP1/RIP3) aggregates.
• While full kinase protein aggregation is studied, the aggregation potential and biomedical applications of RIP1/RIP3 small peptide sequences remain underexplored.

Purpose of the Study:

• To investigate the aggregation propensity, physicochemical properties, and biomedical potential of RIP1/RIP3 RHIM region peptides (4 and 12 amino acids).
• To evaluate the cellular effects and potential of these peptide aggregates as cancer drug depots.

Main Methods:

• Synthesized and characterized amyloid-like aggregates from RIP1/RIP3 peptides of varying lengths.
• Investigated aggregation kinetics, physicochemical properties, and mechanosensitive behaviors.
• Assessed cellular effects and in vitro efficacy when formulated with cisplatin for cancer therapy.

Main Results:

• Peptide concentration and length influence the properties of amyloid-like aggregates.
• RIP1/RIP3 peptide aggregates formulated with cisplatin demonstrated significant lung cancer cell toxicity, enhanced by ultrasound treatment.
• These aggregates show promise as a drug delivery system for cancer therapy.

Conclusions:

• RIP1/RIP3 peptides can form amyloid-like aggregates with tunable properties based on amino acid composition.
• These peptide aggregates represent a novel platform for developing targeted cancer therapies and drug depots.
• Further research into RIP1/RIP3 aggregates could elucidate their roles in cellular functions and diseases.